Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

SAN DIEGO, Feb. 27 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2007.

Total revenues in the fourth quarter of 2007 were $4.6 million, compared to $4.7 million in the fourth quarter of 2006. Total revenues in the full year ended December 31, 2007 were $19.3 million, compared to $30.6 million in the full year ended December 31, 2006, which included a $5.0 million milestone earned under Arena's collaboration with Ortho-McNeil Pharmaceutical, Inc. and a $4.0 million milestone earned under Arena's collaboration with Merck & Co., Inc. Arena reported a net loss allocable to common stockholders in the fourth quarter of 2007 of $40.9 million, or $0.60 per share, and a net loss allocable to common stockholders in the full year ended December 31, 2007 of $145.3 million, or $2.31 per share. This compares with a net loss allocable to common stockholders in the fourth quarter of 2006 of $36.4 million, or $0.73 per share, and a net loss allocable to common stockholders in the full year ended December 31, 2006 of $88.3 million, or $1.89 per share.

"In 2007 we continued our focus on innovative R&D and achieved several important clinical milestones, including the positive lorcaserin month-six ESMB review, positive APD125 Phase 2a data and positive APD791 Phase 1a data," stated Jack Lief, Arena's President and Chief Executive Officer. "In 2008 we will continue to advance our pipeline and R&D efforts, both independently and with our partners. We look forward to the lorcaserin month-12 ESMB review in March and to achieving other important milestones in the coming months."

Research and development expenses totaled $40.7 million
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 6, 2015   University of Maryland (UM) ... today the signing of an exclusive option by Biomecite ... (UMB) to develop diagnostics to detect inflammatory bowel diseases ... (CD). Drs. Florian Fricke and James ... with the University of Maryland School of Medicine,s Institute ...
(Date:5/6/2015)... May 6, 2015 ... specialist, announced today that it has signed an agreement ... PEIX ) for the delivery of an industrial scale ... the consumption of water, energy and emissions ... This project is fully aligned ...
(Date:5/5/2015)... Frederick, MD (PRWEB) May 05, 2015 ... solutions provider released FreezerPro® version 7, the latest major ... management software., Upgrade is a ... Revamped UI succeeds in enhancing users experience, while also ... overall performance, reduces system requirements , Download ...
(Date:5/5/2015)...  23andMe, Inc., the leading personal genetics company, today ... in collaboration with Pfizer Inc. The companies aim ... commonly known as lupus, into the study to help ... also in collaboration with the Lupus Research Institute, and ... Approximately 1.5 million people in the U.S. suffer ...
Breaking Biology Technology:Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3Whitefox Signs Agreement With Pacific Ethanol Inc. 2RURO Releases version 7 of FreezerPro® software 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3
... 2011 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: ... that the United States Patent and Trademark Office (USPTO) has ... D and Fam3C are Biomarkers for Alzheimer,s Disease."  The patent ... as combinations that include these biomarkers. "This patent ...
... and HONG KONG, May 25, 2011 SuperNova ... human and non-human health applications, today announced it ... Valley Association of Startup Entrepreneurs (SVASE) annual Launch: ... campus on Tuesday, June 7, 2011 at 1:15 ...
... Otonomy, Inc., a clinical stage biopharmaceutical company ... the inner and middle ear, today announced the ... operations officer.  Mr. Wroblewski brings the company broad ... supply chain management, packaging and quality assurance.  At ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Alzheimer Patent 2Vermillion Announces Notice of Allowance for Alzheimer Patent 3SuperNova Diagnostics® Selected to Present at Launch: Silicon Valley 2011 2Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 2Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 3
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... translations of a basic research discovery into a promising ... be discussed publicly for the first time by the ... Dec. 14, at the American Society for Cell Biology ... is Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), a rare, ...
... Practice as well as sleep may help birds learn ... during sleep helps young songbirds to develop the vocal ... have found. Sleep is well known to ... processes studied in humans, including acquiring complex skills such ...
... Search & Match,the leading provider of high-performance search ... joined the company as Product Marketing Manager. , ... years of product and marketing management,experience to the ... high-tech products and solutions worldwide. He has deep ...
Cached Biology News:In just 5 years, gene discovery to clinical trial of potential treatment 2In just 5 years, gene discovery to clinical trial of potential treatment 3In just 5 years, gene discovery to clinical trial of potential treatment 4Practice as well as sleep may help birds learn new songs 2Practice as well as sleep may help birds learn new songs 3
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Biology Products: